Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer
Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer
复制标题
DOI：
10.1038/sj.bjc.6603546
复制
发表时间：
2007-01-29
影响因子：
8.8
通讯作者：
Tsutsumi, Y.
中科院分区：
文献类型：
--
作者：
Kamoshida, S.;Suzuki, M.;Tsutsumi, Y.
胸苷酸合成酶（TS）的高表达和p53的失活据称与化疗耐药性相关。作者评价了TS和p53在新辅助S-1/顺铂化疗的胃癌中的表达。对41例胃癌术前活检和手术切除标本的石蜡切片进行TS和p53蛋白的免疫组化染色。51例未经新辅助化疗的病例也进行了研究。在治疗前活检中，TS的高表达见于8%的组织学应答者、28%的无应答者和31%的对照者。p53高表达在无应答者中为56%，而在应答者中为8%，在对照组中为29%（分别为P < 0.01和P < 0.05）。TS-和/或p53-高表型见于76%的无应答者和54%的对照者，但在8%的应答者中（分别为P < 0.0001和P < 0.005）。手术标本的数据与治疗前活检的数据一致。提示TS和p53蛋白的免疫组化染色可用于S-1/顺铂化疗无效的胃癌患者的预处理筛选。
High expression of thymidylate synthase (TS) and inactivation of p53 are allegedly associated with chemoresistance. The authors evaluated TS and p53 expression in gastric cancer treated with neoadjuvant S-1/cisplatin chemotherapy. Paraffin sections of pretreatment biopsy and surgical specimens from 41 gastric cancers were immunostained for TS and p53 protein after appropriate antigen retrieval. Fifty-one cases without neoadjuvant chemotherapy were also studied. In the pretreatment biopsies, high expression of TS was seen in 8% of the histologic responders, in 28% of the nonresponders and in 31% of the controls. High expression of p53 was observed in 56% of the nonresponders, but in 8% of the responders and in 29% of the controls (P < 0.01 and P < 0.05, respectively). The TS- and/or p53-high phenotype was seen in 76% of the nonresponders and in 54% of the controls, but in 8% of the responders (P < 0.0001 and P < 0.005, respectively). The data of the surgical specimens were consistent with those of the pretreatment biopsies. These results suggest that immunostaining for TS and p53 protein is useful for pretreatment selection of gastric cancer patients unresponsive to S-1/cisplatin chemotherapy.